The European Patent Office has issued a patent for SF0166, a topical ophthalmic solution for retinal diseases, according to a press release from SciFluor Life Sciences.
SF0166, a potent and selective small molecule inhibitor of integrin alpha V beta 3, is in clinical development for both diabetic macular edema and neovascular age-related macular degeneration, the release said. It is delivered as an eye drop.
The United States Patent and Trademark Office previously issued five patents for intellectual property protection of SF0166, as well as its methods of use, through 2034.
“The patent
Uncategorized